The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on August ....
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Promoter Hima Bindu Potluri disclosed that a Non-Disposal Undertaking (NDU) on 30,00,000 equity shares (3.38% of total share capital) was released on August 19, 2025, and replaced with a fresh pledge on the same shares on August 20, 2025, in favour of Vistra ITCL (India) Ltd as Debenture Trustee on behalf of Avendus PE Investment Advisors. The net effect is zero change in the number of encumbered shares — it is a swap of the encumbrance type, not a reduction or increase. The pledge is created as security for Non-Convertible Debentures issued by Potluri Laboratories Private Ltd (a promoter group entity), with funds intended for long-term strategic business objectives, working capital, and general corporate purposes. Post-event, Hima Bindu Potluri's encumbered shares stand at 1,36,20,000 (15.36% of total share capital), representing over 50% of her individual promoter shareholding and over 20% of total share capital on a combined promoter encumbrance basis.
No change in overall promoter encumbered position — this is a technical restructuring of the encumbrance from NDU to pledge with the same counterparty, so no direct dilution or change in promoter control. However, the high level of pledged shares (over 50% of the individual promoter's holding) means shareholders should monitor any future pledge invocation, which could pressure the stock.